Company Encyclopedia
View More
name
Reviva Pharmaceuticals
RVPH.US
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
4.396 T
RVPH.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Alliance Global Partners Sticks to Their Buy Rating for Reviva Pharmaceuticals Holdings (RVPH)

    Alliance Global Partners analyst James Molloy reiterated a Buy rating for Reviva Pharmaceuticals Holdings, setting a price target of $16.00. Molloy, who covers the Healthcare sector, has an average return of -26.0% and a 23.12% success rate on recommended stocks. Reviva Pharmaceuticals Holdings has a consensus Strong Buy rating with a price target of $5.14.

    Tip Ranks·
    US
    RVPH
    -6.32%
    Tip Ranks·
    US
    RVPH
    -6.32%

    Reviva Pharmaceuticals | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    RVPH
    -6.32%
    LB filings·
    US
    RVPH
    -6.32%

    Reviva Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    RVPH
    -6.32%
    LB filings·
    US
    RVPH
    -6.32%

    Reviva Pharmaceuticals Q3 net loss narrows

    Reviva Pharmaceuticals reported a Q3 net loss of $4 million, an improvement from last year's $8.4 million loss. The company plans a pre-NDA meeting with the FDA for brilaroxazine in Q4 2025 and received a European patent for brilaroxazine in pulmonary fibrosis. They raised $9 million through a public equity offering. Analysts rate the stock as a "buy," with a median 12-month price target of $3.00, significantly above the current price.

    Reuters·
    US
    RVPH
    -6.32%
    Reuters·
    US
    RVPH
    -6.32%

    Reviva Pharmaceuticals Q3 EPS USD -0.06

    Nov 13 (Reuters) - Reviva Pharmaceuticals Q3 net income USD -4 million.

    Reuters·
    US
    RVPH
    -6.32%
    Reuters·
    US
    RVPH
    -6.32%